Cannabis Investment Report – Tax and Regulatory Risks (Dec 2017)
Summary
The passage outlines generic regulatory and tax challenges for cannabis businesses without naming specific individuals, companies, or transactions. It offers no actionable leads, novel information, or Federal tax law prevents cannabis businesses from deducting many expenses, raising effective tax rat Banking restrictions force cannabis firms to operate largely in cash. Federal trademark and bankru
This document is from the House Oversight Committee Releases.
View Source CollectionPersons Referenced (1)
Tags
Related Documents (6)
Cannabis Investment Report – December 2017 Overview of Distribution and Regulatory Landscape
The passage is a generic industry analysis without specific names, transactions, dates, or concrete allegations involving high‑profile officials or entities. It offers only broad context about tax and Highlights tax compliance risks for cannabis distributors across U.S. states. Notes potential market saturation and licensing moratoriums in Colorado. Mentions California’s new cannabis regulatory ag
Cannabis Investment Report – Market Overview and Funding Landscape (Dec 2017)
The document is a generic industry analysis with no mention of high‑profile political figures, intelligence agencies, or controversial financial flows. It provides market commentary and fundraising to Reports $2.0 billion raised by cannabis‑related companies in 2017. Highlights Canadian exchanges (TSX, TSXV, CSE) as primary venues for cannabis listings. Notes ongoing U.S. federal prohibition limit
Cowen Cannabis Valuation Methodology Highlights Federal Legal Risks
The passage is a standard investment research note describing valuation methods and regulatory risks for cannabis companies. It contains no specific allegations, names, transactions, or actionable lea Uses EV‑to‑Sales multiples for cannabis company valuation. Notes that cannabis remains illegal under federal law (CSA). Mentions potential criminal prosecution risk for U.S. cannabis firms.
Cannabis Investment Report – Market Outlook and Business Solutions (Dec 2017)
The document provides generic industry analysis and investment considerations for cannabis businesses. It contains no specific references to high‑ranking officials, political actors, foreign leaders, Emphasizes building relationships with dispensary operators for shelf placement. Discusses risks and costs of obtaining FDA approval for cannabis‑derived drugs. Notes potential product liability expo
Cronos Group partners with Ginkgo Bioworks to develop cultured cannabinoids valued up to $122M
The passage details a commercial biotech partnership between a Canadian cannabis firm and a synthetic biology startup. It provides financial terms and milestones but does not implicate high‑ranking po Agreement announced September 2018 between Cronos Group and Ginkgo Bioworks. Total deal value up to $122 million, including $22 million R&D funding and up to $100 million in Cro Ginkgo to engineer ye
Synthetic biology and QA/QC testing market for cannabinoids
The passage is a commercial market analysis describing production methods and testing opportunities for CBD. It mentions no high‑profile officials, agencies, or controversial financial flows, and prov Synthetic biology can produce cannabinoids via fermentation. QA/QC testing standards for CBD are currently fragmented across states. Life‑science instrument makers (Agilent, Danaher, PerkinElmer, Shi
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.